Atea Pharmaceuticals, Inc. (AVIR) vs Editas Medicine, Inc. (EDIT)
A side-by-side comparison of Atea Pharmaceuticals, Inc. and Editas Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVIR
Atea Pharmaceuticals, Inc.
$5.02HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
EDIT
Editas Medicine, Inc.
$2.81HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — AVIR vs EDIT
growth of $100 · dividends reinvested · last 6yAVIR -83.1% (-25.6%/yr)EDIT -91.5% (-33.7%/yr)AVIR compounded faster over this window
AVIR EDIT
AVIR vs EDIT: by the numbers
- •EDIT is the larger company ($430M vs $401M market cap).
- •Both run net losses; AVIR's is the smaller (0.00% vs -157.32% net margin).
Metrics side by side
Valuation
| Metric | AVIR | EDIT |
|---|---|---|
| P/S ratio | N/A | 9.16 |
| P/B ratio | 1.97 | 4.09 |
Profitability
| Metric | AVIR | EDIT |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -245.15% |
| Net margin | 0.00% | -157.32% |
| ROE | -80.96% | -70.24% |
| ROIC | -89.93% | -48.61% |
Growth (annualized)
| Metric | AVIR | EDIT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -10.34% |
| Total return CAGR (5Y) | -34.44% | -40.76% |
Frequently asked
- How have AVIR and EDIT total returns compared?
- Over the past 5 years, AVIR delivered -34.44% and EDIT delivered -40.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.